JP2005513416A5 - - Google Patents

Download PDF

Info

Publication number
JP2005513416A5
JP2005513416A5 JP2003525032A JP2003525032A JP2005513416A5 JP 2005513416 A5 JP2005513416 A5 JP 2005513416A5 JP 2003525032 A JP2003525032 A JP 2003525032A JP 2003525032 A JP2003525032 A JP 2003525032A JP 2005513416 A5 JP2005513416 A5 JP 2005513416A5
Authority
JP
Japan
Prior art keywords
receptor
amino acid
acid sequence
proline
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003525032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513416A (ja
JP4467973B2 (ja
Filing date
Publication date
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/en
Application filed filed Critical
Priority claimed from PCT/AU2002/001204 external-priority patent/WO2003020762A1/en
Publication of JP2005513416A publication Critical patent/JP2005513416A/ja
Publication of JP2005513416A5 publication Critical patent/JP2005513416A5/ja
Application granted granted Critical
Publication of JP4467973B2 publication Critical patent/JP4467973B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003525032A 2001-09-03 2002-09-03 非機能性ｐ２ｘ７リセプターに対応する抗体、癌及びその他の症状の診断及び治療 Expired - Lifetime JP4467973B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7430 2001-09-03
AUPR7431 2001-09-03
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
PCT/AU2002/000061 WO2002057306A1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
AUPCT/AU02/00061 2002-01-17
PCT/AU2002/001204 WO2003020762A1 (en) 2001-09-03 2002-09-03 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions

Publications (3)

Publication Number Publication Date
JP2005513416A JP2005513416A (ja) 2005-05-12
JP2005513416A5 true JP2005513416A5 (https=) 2008-05-15
JP4467973B2 JP4467973B2 (ja) 2010-05-26

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003525032A Expired - Lifetime JP4467973B2 (ja) 2001-09-03 2002-09-03 非機能性ｐ２ｘ７リセプターに対応する抗体、癌及びその他の症状の診断及び治療

Country Status (9)

Country Link
JP (1) JP4467973B2 (https=)
CN (2) CN100497386C (https=)
AU (1) AU2002322192B2 (https=)
CA (1) CA2459348C (https=)
MY (1) MY142283A (https=)
NZ (2) NZ549019A (https=)
TW (1) TWI329648B (https=)
WO (1) WO2003020762A1 (https=)
ZA (1) ZA200402630B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
WO2004053426A1 (en) * 2002-12-05 2004-06-24 Kla-Tencor Technologies Corporation Apparatus and methods for detecting overlay errors using scatterometry
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
CN101469352B (zh) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 一种早期子宫癌原位杂交检测试剂盒
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) * 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置

Similar Documents

Publication Publication Date Title
JP2005513416A5 (https=)
Korb et al. Use of monoclonal antibody–IRDye800CW bioconjugates in the resection of breast cancer
CN100497385C (zh) 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
EP3634500B1 (en) Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
CN100497386C (zh) 非功能性p2x7受体的抗体及其应用
JP2004528286A5 (https=)
RU2013123792A (ru) Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний
Hartimath et al. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
Chen et al. Detection of Barrett’s neoplasia with a near-infrared fluorescent heterodimeric peptide
JP2024520616A (ja) 交流電場とトラスツズマブの組合せを用いて処置するための組成物及び方法
CN112661812B (zh) 一种kk-lc-1抗原靶向结合肽及其衍生物、探针与应用
Sputa‐Grzegrzolka et al. Laugier‐Hunziker syndrome: a case report of the pediatric patient and review of the literature
Gan et al. A Phase 1 and Biodistribution Study of ABT-806i, An 111Indium-Labeled Conjugate of theTumor-Specific Anti-EGFR Antibody ABT-806
Pasanen et al. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study
Koo et al. Ornithine decarboxylase levels in the rectal mucosa of patients with colonic neoplasia
CN101962405A (zh) 一种人源乳腺癌抗原及其抗体
CN114599675A (zh) 用于治疗clouston型外胚层发育不良2的组合物和方法
CN121422259A (zh) 一种基于抗组织因子抗体的诊断放射性药物及其制备方法和应用
Wang et al. General Introduction of PET/CT of Neck Neoplasms
AU2024210360A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
Henry Production, characterisation and clinical application of monoclonal antibodies to the human oestrogen and progesterone receptors.
Higo et al. Laryngeal edema in a patient with dermatomyositis
Glass Mottled Skin Changes
Swanston et al. Clinical PET/CT in oncology
Riedel et al. Expression of epidermal growth factor receptor in lymph node metastases of head and neck squamous cell carcinomas